Evidence map›Paper›PMID 42576720›Full record

ArticleJournal of Korean medical science2026

Real-World Treatment Patterns for Waldenstrom Macroglobulinemia: Implications for Treatment Sequencing.

Seo Yoon Jang, Ja Min Byun, Sung-Soo Park, Youngju Kim, Jeongmin Park, Dong-Yeop Shin, Youngil Koh, Inho Kim, Chang Ki Min, Sung-Soo Yoon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Seo Yoon JangDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID https://orcid.org/0009-0000-9129-3838
Ja Min ByunDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0003-1780-5553
Sung-Soo ParkDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. sspark@catholic.ac.kr.ORCID https://orcid.org/0000-0002-8826-4136
Youngju KimCancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-9176-1168
Jeongmin ParkCancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0009-0008-1376-5420
Dong-Yeop ShinDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0003-1753-8846
Youngil KohDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0002-4750-931X
Inho KimDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0002-8785-6201
Chang Ki MinDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0002-1940-0392
Sung-Soo YoonDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0003-2591-7459

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDue to the rarity of Waldenstrom macroglobulinemia (WM) and scarcity of direct comparative data, there remains uncertainty regarding the optimal therapeutic approach for treatment-naïve patients and subsequent treatment sequence. To bridge such knowledge gap and generate data on most appropriate treatment in relatively resource constraint setting, we conducted this study with 168 WM patients.

methodsDue to the diversity of treatment regimens, patients were categorized into four groups: cytotoxic regimen, rituximab-based regimen, proteasome inhibitor (PI)/immunomodulatory drug (IMiD)-based regimen, and bruton tyrosine kinase inhibitor (BTKi). Treatment patterns and efficacy outcomes were analyzed.

resultsThe overall response rate (ORR) between rituximab-based vs. PI/IMiD based regimens were similar (74.2% vs. 80.0%,

conclusionOur findings underscore the importance of optimizing treatment strategies and offer real-world data to support informed decision-making in settings with constrained resources.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsWaldenstrom MacroglobulinemiaAdultAgammaglobulinaemia Tyrosine KinaseAgedAged, 80 and overFemaleHumansImmunologic FactorsMaleMiddle AgedProgression-Free SurvivalProteasome InhibitorsProtein Kinase InhibitorsRetrospective StudiesRituximabAgammaglobulinaemia Tyrosine KinaseBTK protein, humanImmunologic FactorsProteasome InhibitorsProtein Kinase InhibitorsRituximabImmunomodulatory DrugsProteasome InhibitorsRituximabWaldenstrom Macroglobulinemia

Identifiers

PMID42576720
PMCPMC13457695

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.